The prospect of an October OK largely closed, Pfizer's Albert Bourla promises not to submit for EUA until November
For weeks in late summer and early fall, Pfizer CEO Albert Bourla insisted they would likely know whether their vaccine works by the end of October and then “immediately” submit for an FDA OK, fueling concerns that President Trump could push through a politically motivated EUA on the eve of Election Day. But now, in the latest of a series of moves that appeared designed to distance his company from a potential political maelstrom, Bourla has made clear they won’t go to regulators for about another month.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.